Cargando…

The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma

BACKGROUND: Whether radiologically detected progressive disease (PD) is an accurate metric for discontinuing sorafenib treatment in patients with hepatocellular carcinoma (HCC) is unclear. We investigated the efficacy of sorafenib treatment after radiologic confirmation of PD in patients with advanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wada, Yoshiyuki, Takami, Yuko, Tateishi, Masaki, Ryu, Tomoki, Mikagi, Kazuhiro, Saitsu, Hideki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706384/ https://www.ncbi.nlm.nih.gov/pubmed/26745625 http://dx.doi.org/10.1371/journal.pone.0146456

Ejemplares similares

Impact of more detailed categorization of shrinkage or progression ratio at initial imaging response after sorafenib treatment in advanced hepatocellular carcinoma patients
por: Wada, Yoshiyuki, et al.
Publicado: (2015)

Long-Term Maintenance of Complete Response after Sorafenib Treatment for Multiple Lung Metastases from Hepatocellular Carcinoma
por: Katafuchi, Eisuke, et al.
Publicado: (2015)

A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment
por: Takami, Yuko, et al.
Publicado: (2016)

Efficacy of surgical treatment using microwave coagulo-necrotic therapy for unresectable multiple colorectal liver metastases
por: Wada, Yoshiyuki, et al.
Publicado: (2016)

The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Wada, Yoshiyuki, et al.
Publicado: (2017)

A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression
por: Wada, Yoshiyuki, et al.
Publicado: (2020)

Evaluation of intraoperative microwave coagulo-necrotic therapy (MCN) for hepatocellular carcinoma: a single center experience of 719 consecutive cases
por: Takami, Yuko, et al.
Publicado: (2012)

Feasibility and safety of surgical microwave ablation for hepatocellular carcinoma in elderly patients: a single center analysis in Japan
por: Imamura, Hajime, et al.
Publicado: (2020)

Predictive Factors for Local Recurrence after Intraoperative Microwave Ablation for Colorectal Liver Metastases
por: Wada, Yoshiyuki, et al.
Publicado: (2022)

Glomus tumor of the duodenum: a rare case report
por: Sasaki, Shin, et al.
Publicado: (2020)

Conversion surgery for initially unresectable carcinoma of the ampulla of Vater following pathological complete response to chemotherapy: a case report
por: Sato, Yo, et al.
Publicado: (2019)

A case of small cell neuroendocrine carcinoma of the ampulla of Vater
por: Ito, Hiroharu, et al.
Publicado: (2020)

Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report
por: Okuwaki, Yusuke, et al.
Publicado: (2012)

Long-term survival of a patient with recurrent gallbladder carcinoma, treated with chemotherapy, immunotherapy, and surgery: a case report
por: Kawamoto, Makoto, et al.
Publicado: (2018)

Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy
por: Saeki, Issei, et al.
Publicado: (2018)

Rapid long-lasting biochemical and radiological response to sorafenib in a case of advanced hepatocellular carcinoma
por: GERARDI, ASSUNTA MARIA TERESA, et al.
Publicado: (2013)

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
por: El Dika, Imane, et al.
Publicado: (2020)

Sorafenib-Related Adverse Events in Predicting the Early Radiologic Responses of Hepatocellular Carcinoma
por: Lee, Shou-Wu, et al.
Publicado: (2019)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy
por: Saeki, Issei, et al.
Publicado: (2019)

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Shi, Tingting, et al.
Publicado: (2021)

Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib
por: Otsuka, Taiga, et al.
Publicado: (2015)

Factors Affecting Therapeutic Effects in 17 Patients with Advanced Hepatocellular Carcinoma Who Were Treated with Sorafenib for More than 12 Months
por: Katayama, Kazuhiro, et al.
Publicado: (2018)

Acalculous Cholecystitis in a Patient with Hepatocellular Carcinoma on Sorafenib
por: Sanda, Mariko, et al.
Publicado: (2011)

Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response
por: Zhang, Yingqiang, et al.
Publicado: (2015)

Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma
por: Ha, Yeonjung, et al.
Publicado: (2016)

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
por: Yamashita, Tatsuya, et al.
Publicado: (2019)

Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
por: Lee, Sangheun, et al.
Publicado: (2013)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib
por: Pelosof, Lorraine, et al.
Publicado: (2018)

Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure
por: Cheng, Tsung-Yi, et al.
Publicado: (2020)

Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
por: SHAO, WENBO, et al.
Publicado: (2014)

Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
por: Huang, Song-Fong, et al.
Publicado: (2022)

Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma
por: Iwamoto, Hideki, et al.
Publicado: (2021)

Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study
por: Nakano, Masahito, et al.
Publicado: (2016)

Clinical and radiological diversity in genetically confirmed primary familial brain calcification
por: Koyama, Shingo, et al.
Publicado: (2017)

Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma
por: Zhao, Yang, et al.
Publicado: (2019)

Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma
por: Hagihara, Atsushi, et al.
Publicado: (2014)

Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma
por: Kohno, Tomoki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m9kl1a59odkg1t7o91l3ut5u1m